Home CONTACT Neoplasma Ahead of print Neoplasma Vol.69, No.3, p.504–515, 2022

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.69, No.3, p.504–515, 2022

Title: Drug therapy for bone metastasis of malignant tumor: theory, progress, and potential
Author: Ji-Zheng Tian, Ni-Na Ma, Xiao Li, Kun Shang, Bang-Wei Cao

Abstract: Bone is a common metastatic site of malignancies, caused by the complex interaction between tumor cells and the bone microenvironment. The complicated procedure covers multiple targets for therapeutic strategies against bone metastasis. At the present, only bisphosphonates and denosumab are currently approved for the prevention of skeletal-related events. But it is still ineffective for some patients, and none of them are proven to prolong the overall survival of patients with bone metastasis. Thus, new bone-modifying agents and therapeutic strategies are required. The review aimed to generalize the basic theory of bone metastasis and major put emphasis on the development of fundamental and potential target drugs in the behavior of bone metastasis. The summary of the drug development process helps to provide ideas for finding new and effective treatments for bone metastasis.

Keywords: bone metastasis; bone microenvironment; bone-modifying agents; skeletal-related events
Published online: 01-Feb-2022
Year: 2022, Volume: 69, Issue: 3 Page From: 504, Page To: 515

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.